An Open-label, Non-comparative Study to Assess the Long-term Safety, Tolerability, and Efficacy of Ipragliflozin in Combination With GLP-1 Receptor Agonists in Japanese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control With GLP-1 Receptor Agonists

Trial Profile

An Open-label, Non-comparative Study to Assess the Long-term Safety, Tolerability, and Efficacy of Ipragliflozin in Combination With GLP-1 Receptor Agonists in Japanese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control With GLP-1 Receptor Agonists

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs Ipragliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 21 Jul 2017 Last checked against ClinicalTrials.gov.record.
    • 10 Jun 2017 Biomarkers information updated
    • 23 Aug 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top